Neuroblastoma-Targeted Nanoparticles and Novel Nanotechnology-Based Treatment Methods Publisher Pubmed



Mobasheri T^{1, 2} ; Rayzan E^{1, 3} ; Shabani M^{3, 4} ; Hosseini M⁵ ; Mahmoodi Chalbatani G⁶ ; Rezaei N^{3, 7, 8} Show Affiliations
Source: Journal of Cellular Physiology Published:2021

Abstract

Neuroblastoma is a complicated pediatric tumor, originating from the neural crest, which is the most prevalent in adrenal glands, but may rarely be seen in some other tissues as well. Studies are focused on developing new strategies through novel chemo- and immuno-therapeutic drug targets. Different types of oncogenes such as MYCN, tumor suppressor genes such as p53, and some structural genes such as vascular endothelial growth factor are considered as targets for neuroblastoma therapy. The individual expression patterns in NB cells make them appropriate for this purpose. The combined effect of nano-drug delivery systems and specific drug targets will result in lower systemic side effects, prolonged therapeutic effects, and improvements in the pharmacokinetic properties of the drugs. Some of these novel drug delivery systems with a focus on liposomes as carriers are also discussed. In this review, genes and protein products that are beneficial as drug targets in the treatment of neuroblastoma have been discussed. © 2020 Wiley Periodicals LLC